Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. May 15, 2025; 17(5): 105148
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.105148
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.105148
Table 1 Characteristics of studies included in the meta-analysis
Ref. | Country | Study type | Cut-off value | Method of measurement | Average age (years) | No. of patients (female/male) | Follow-up time (years) |
Tseng et al[26], 2022 | China | Cohort | HBcrAg > 4.0 LogU/mL | NA | 42.4 ± 10.1 | 990 (351/639) | Mean = 15.88 |
Hosaka et al[16], 2022 | Japan | Cohort | iTACT-HBcrAg > 2.9 LogU/mL | iTACT | 51.0 ± 9.9 | 180 | Median = 11.0 |
Hsieh et al[18], 2023 | China | Case-control | HBcrAg ≥ 3.0 LogU/mL | CLEIA | 55.0 (49.0-60.0) | 649 (245/404) | 1991-2014 |
Kaneko et al[19], 2021 | Japan | Cohort | HBcrAg > 4.1 LogU/mL | CLEIA | 54.0 (20.0-85.0) | 139 | Median = 5.3 |
Suzuki et al[23], 2021 | Japan | Case-control | iTACT-HBcrAg > 2.7 LogU/mL | iTACT | 80.3 (44.0-70.0) | 17 (5/12) | Not available |
Liang et al[22], 2020 | China | Cohort | HBeAg-positive cohort: HBcrAg > 4.9 LogU/mL | CLEIA | 53.5 ± 11.8 | 1400 (387/1013) | Mean = 3.75 |
To et al[25], 2019 | China | Cohort | HBcrAg > 5.12 LogU/mL | CLEIA | 40.0 (34.0-45.0) | 207 (89/118) | Median = 13.1 |
Tseng et al[27], 2019 | China | Cohort | HBcrAg ≥ 4.0 LogU/mL | CLEIA | 41 | 1211 (1050/161) | Mean = 15.95 |
Suzuki et al[24], 2019 | Japan | Cross-sectional | HBcrAg ≥ 3.0 LogU/mL | CLEIA | 54.8 | 449 (296/153) | Not available |
Hosaka et al[17], 2019 | Japan | Cohort | HBeAg-negative cohort: HBcrAg > 4.30 LogU/mL | CLEIA | 44.0 (34.0-57.0) | 1268 (339/929) | Median = 8.9 |
Ando et al[12], 2018 | Japan | Cohort | HBcrAg > 3.4 LogU/mL | CLEIA | 51.0 (20.0-79.0) | 133 (54/79) | Median = 4.8 |
Chen et al[13], 2018 | China | Cohort | HBcrAg > 5.2 LogU/mL | CLEIA | 52.5 (30.0-87.0) | 56 | Median = 5.0 |
Cheung et al[14], 2017 | China | Case-control | HBcrAg ≥ 3.89 LogU/mL | CLEIA | HCC: 61.3 (54.8-66.8) | 228 (39/189) | Not available |
Tada et al[28], 2016 | Japan | Cohort | HBcrAg > 2.9 LogU/mL | CLEIA | 49.0 (35.0-59.5) | 1031 (473/558) | Median = 10 |
Honda et al[15], 2016 | Japan | Cohort | HBcrAg > 3.0 LogU/mL | CLEIA | 52.0 (30.0-79.0) | 109 (33/76) | Mean = 6.5 |
Kumada et al[20], 2013 | Japan | Cohort | HBcrAg > 2.9 LogU/mL | CLEIA | 52.0 (21.0-77.0) | 234 (89/145) | Median = 13.0 |
Kusakabe et al[21], 2011 | Japan | Cohort | Not mentioned | CLEIA | 55.2 ± 8.5 | 479 (259/220) | Mean = 12.7 |
- Citation: Liang LB, Zhang HJ, Liu F, Su QL. Hepatitis B core-related antigen as a predictive biomarker for recurrence in primary hepatocellular carcinoma: A meta-analysis. World J Gastrointest Oncol 2025; 17(5): 105148
- URL: https://www.wjgnet.com/1948-5204/full/v17/i5/105148.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.105148